Guangzhou Jinqirui Biotechnology
Precision molecular diagnostics and NGS solutions
About Guangzhou Jinqirui Biotechnology
Guangzhou Jinqirui Biotechnology Co., Ltd., also known as KingCreate Biotechnology, was founded in 2016 and is headquartered in Guangzhou, China. The company specializes in the research, development, production, and sales of in-vitro diagnostic products for precision medicine. It aims to provide localized precision molecular diagnostic solutions for various medical institutions.
The firm has developed proprietary technologies in multiplex PCR, ultra-multiplex targeted sequencing (tNGS), and metagenomics (mNGS), which have applications in oncology and infectious diseases. Its product portfolio includes genetic sequencers like the KM MiniSeqDx-CN system, automated sample processing systems, nucleic acid extractors, and various testing kits. Notably, its respiratory pathogen and HPV testing kits received CE certification in 2022, and the company obtained NMPA (National Medical Products Administration) registration for its gene sequencer in 2020 and a multi-gene tumor test kit in 2022. This makes it one of the few domestic companies in China offering a complete solution for tumor companion diagnostics, including the sequencer, clinical applications, and software.
The company serves the diagnostic equipment and biotechnology industries, with a focus on life sciences and oncology. Its business model involves providing these integrated diagnostic systems and related reagents to medical facilities. KingCreate Biotechnology is a privately held, venture capital-backed company. It has completed multiple funding rounds, including a Series A in 2019, Series B in 2020, and a Series C in August 2023. Key investors include Legend Capital, E Fund Management, Aurora Private Equity, and China Development Bank Capital.
Source: Dealroom company dataNews
Open roles
Guangzhou Jinqirui Biotechnology in the Guangzhou ecosystem
The Guangzhou Jinqirui Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Legend Capital
E Fund Management
Series B and later2 investors entered at this stage
Chenhui Venture Partners- SJShengjing Jiacheng
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Guangzhou Jinqirui Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Guangzhou Jinqirui Biotechnology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.